Journal of Clinical Medicine

Journal Browser

► Journal Browser

Updates in Ischemic Heart Disease: Pathogenesis, Treatment, and Future Perspectives

Share This Special Issue

Special Issue Editor

Special Issue Information

Dear Colleagues,

Ischemic heart disease (IHD) still represents the leading cause of disability and mortality worldwide, and in recent years, IHD has been widely identified with the presence of obstructive coronary artery disease (CAD). However, a significant number of patients presenting with known or suspected angina or myocardial infarction (MI) do not have obstructive CAD, and therefore, the pathogenesis of IHD has been expanded. Accordingly, the treatment and prevention of IHD have been updated, and recent advances in pharmacological and interventional therapeutic modalities have allowed the implementation of patient-tailored treatments and the improvement of prognosis. To better examine this complicated disease and to provide updates and perspectives, this Special Issue of JCM is interested in articles that provide insights into the pathogenesis and treatment of IHD. In particular, the issue will focus on research on all the pathogenetic mechanisms and potential therapeutic aspects of IHD, ranging from obstructive CAD to ischemia with non-obstructive coronary artery disease (INOCA) and MI with non-obstructed coronary arteries (MINOCA), potentially inspiring further research in their management. This Special Issue on “Updates in Ischemic heart disease: Pathogenesis, Treatment, and Future Perspectives” aims to focus on both basic science and translational research, as well as clinical evidence in order to have a more detailed comprehension of the different pathogenetic mechanisms to target when managing IHD.

Prof. Dr. Rocco Antonio Montone
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.

Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.

Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.

External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.

e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

11 pages, 1409 KiB

Open AccessArticle

Mid-Term Outcome of Ventricular Arrhythmias Catheter Ablation in Patients with Chronic Coronary Total Occlusion Compared to Ischemic and Non-Ischemic Patients

by Maria Lucia Narducci, Giampaolo Niccoli, Francesco Flore, Francesco Perna, Gianluigi Bencardino, Rocco Antonio Montone, Gemma Pelargonio and Filippo Crea

J. Clin. Med. 2022, 11(23), 7181; https://doi.org/10.3390/jcm11237181 - 2 Dec 2022

Cited by 1 | Viewed by 1615

Abstract

Chronic coronary total occlusions (CTO) are considered an emerging predictor of ventricular arrhythmias (VAs), but currently there are few data on arrhythmic outcomes in patients affected by CTO undergoing radiofrequency catheter ablation of VAs. This study sought to evaluate the impact of unrevascularized CTO on the recurrence of VAs after catheter ablation. This was a single-center retrospective study enrolling 120 patients between 2015 and 2020. All patients were admitted for ventricular tachycardia (VT) or high premature ventricular contractions burden (>25% detected by Holter ECG), without evidence of acute coronary syndrome; they underwent coronary angiography, electrophysiology (EP) study, and three-dimensional electroanatomic mapping (3D-EAM) followed by VAs ablation. Twenty-eight patients (23%) of 120 patients showed CTO at coronary angiography. At baseline, the CTO group presented with higher prevalence of hypertension, chronic renal disease, systolic ventricular dysfunction, secondary prevention ICD implantation, and higher rate of LAVA by 3D-EAM compared with the non-CTO group. At a median follow-up of 15 months (range 1–96 months) after catheter ablation, the only independent predictor of VAs recurrence was the presence of moderate to severe left ventricular (LV) dysfunction. Therefore, the presence of CTO does not predict VAs recurrence after catheter ablation, which is instead predicted by LV dysfunction. Full article

(This article belongs to the Special Issue Updates in Ischemic Heart Disease: Pathogenesis, Treatment, and Future Perspectives)

► Show Figures

Figure 1

14 pages, 4566 KiB

Open AccessArticle

Myocardial Injury Portends a Higher Risk of Mortality and Long-Term Cardiovascular Sequelae after Hospital Discharge in COVID-19 Survivors

by Riccardo Rinaldi, Mattia Basile, Carmine Salzillo, Domenico Luca Grieco, Andrea Caffè, Carlotta Masciocchi, Livia Lilli, Andrea Damiani, Giulia La Vecchia, Giulia Iannaccone, Alice Bonanni, Gennaro De Pascale, Rita Murri, Massimo Fantoni, Giovanna Liuzzo, Tommaso Sanna, Massimo Massetti, Antonio Gasbarrini, Vincenzo Valentini, Massimo Antonelli, Filippo Crea, Rocco Antonio Montone and on behalf of the Gemelli against COVID Group Show full author list Hide full author list

J. Clin. Med. 2022, 11(19), 5964; https://doi.org/10.3390/jcm11195964 - 10 Oct 2022

Cited by 14 | Viewed by 3157

Abstract

Background: Cardiovascular sequelae after COVID-19 are frequent. However, the predictors for their occurrence are still unknown. In this study, we aimed to assess whether myocardial injury during COVID-19 hospitalization is associated to CV sequelae and death after hospital discharge. Methods: In this prospective observational study, consecutive patients who were admitted for COVID-19 in a metropolitan COVID-19 hub in Italy, between March 2021 and January 2022, with a ≥ 1 assessment of high sensitivity cardiac troponin I (hs-cTnI) were included in the study, if they were alive at hospital discharge. Myocardial injury was defined as elevation hs-cTnI > 99th percentile of the upper reference limit. The incidence of all-cause mortality and major adverse cardiovascular and cerebrovascular events (MACCE, including cardiovascular death, admission for acute or chronic coronary syndrome, hospitalization for heart failure, and stroke/transient ischemic attack) at follow-up were the primary outcomes. Arrhythmias, inflammatory heart diseases, and/or thrombotic disorders were analyzed as well. Results: Among the 701 COVID-19 survivors (mean age 66.4 ± 14.4 years, 40.2% female), myocardial injury occurred in 75 (10.7%) patients. At a median follow-up of 270 days (IQR 165, 380), all-cause mortality (21.3% vs. 6.1%, p < 0.001), MACCE (25.3% vs. 4.5%, p < 0.001), arrhythmias (9.3% vs. 5.0%, p = 0.034), and inflammatory heart disease (8.0% vs. 1.1%, p < 0.001) were more frequent in patients with myocardial injury compared to those without. At multivariate analysis, myocardial injury (HR 1.95 [95% CI:1.05–3.61]), age (HR 1.09 [95% CI:1.06–1.12]), and chronic kidney disease (HR 2.63 [95% CI:1.33–5.21]) were independent predictors of death. Myocardial injury (HR 3.92 [95% CI:2.07–7.42]), age (HR 1.05 [95% CI:1.02–1.08]), and diabetes (HR 2.35 [95% CI:1.25–4.43]) were independent predictors of MACCE. Conclusion: In COVID-19 survivors, myocardial injury during the hospital stay portends a higher risk of mortality and cardiovascular sequelae and could be considered for the risk stratification of COVID-19 sequelae in patients who are successfully discharged. Full article

(This article belongs to the Special Issue Updates in Ischemic Heart Disease: Pathogenesis, Treatment, and Future Perspectives)

► Show Figures

Journal Menu

Journal Browser

Updates in Ischemic Heart Disease: Pathogenesis, Treatment, and Future Perspectives

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Published Papers (2 papers)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI